Showing 2381-2390 of 23151 results for "".
The Technical Assistance You’ll Need for the Quality Payment Programs Changes
https://reachmd.com/programs/perspectives-ama/the-technical-assistance-youll-need-for-the-quality-payment-programs-changes/9975/Dr. Edward Sobel and Ms. Temaka Williams explains what technical assistance is needed during Quality Payment Program updates in your practice.The Patient-Centered Medical Home: Does It Work for Primary Care?
https://reachmd.com/programs/primary-care-today/the-patient-centered-medical-home-does-it-work-for-primary-care/6776/The Patient-Centered Medical Home is a frequently discussed model for improving general practice, but converting from an ideal to a practical reality has been difficult for many clinicians on the front lines of care. Speaking on the triumphs and setbacks of this transitional period in practice is DrADHD Meets Public Policy
https://reachmd.com/programs/focus-on-public-health-policy/adhd-meets-public-policy/3691/Pediatric attention deficit hyperactivity disorder (ADHD) is a controversial diagnosis and everybody has an opinion on medications like Ritalin. Dr. Rick Mayes, associate professor of public policy at the University of Richmond's department of political science and a faculty research fellow at the PIntegrative Medicine Approach to Cancer Treatment
https://reachmd.com/programs/clinicians-roundtable/integrative-medicine-approach-to-cancer-treatment/2553/Most patients want access to every tool available to them while battling cancer and often look to their physicians for help. In addition to chemotherapy and radiation, there are many non-conventional treatment options to consider, many of which complement the impact of radiation and chemotherpy. JoiDESTINY-Breast11: Clinically Relevant Adverse Events
https://reachmd.com/clinical-practice/oncology-hematology/destiny-breast11-clinically-relevant-adverse-events/48988/Tune in to explore the clinically relevant safety profile of T-DXd–based neoadjuvant therapy in high-risk HER2+ early breast cancer from DESTINY-Breast11.Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing
https://reachmd.com/programs/medical-industry-feature/rise-in-early-onset-colon-cancer-being-studied-through-single-cell-sequencing/29922/What’s behind the rise in colon cancer in younger patients? Listen to a breakdown of key trends, possible causes, and ongoing research to find answers.Key Considerations for G-CSF Administration in Patients with FN Risk
https://reachmd.com/programs/medical-industry-feature/key-considerations-for-g-csf-administration-in-patients-with-fn-risk/13123/Here’s what you need to keep in mind when administering granulocyte colony stimulating factors for primary prophylaxis of febrile neutropenia.Managing Eye-Related Adverse Events Caused by Cancer Treatments
https://reachmd.com/programs/medical-industry-feature/managing-eye-related-adverse-events-caused-by-cancer-treatments/36171/Some cancer medicines may cause problems with the eyes or with vision.1-3 Most of these eye-related adverse events can be mild, brief, intermittent, and reversible,1,3-6 but others may be long-lasting and could involve permanent vision loss or structural changes of the eye.1,2,7 As a result, it’s imFrom Monoamines to Neurocircuits: Our Evolving Understanding of Depression
https://reachmd.com/programs/medical-industry-feature/monoamines-neurocircuits-understanding-depression/29735/Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept ofTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
https://reachmd.com/clinical-practice/cardiology/targeting-epicardial-adipose-tissue-in-patients-with-hfpef-without-diabetes-sotagliflozin-effect-from-sota-p-cardia-trial-sub-analysis/49274/Review SOTA-P-CARDIA sub-analysis findings on the effects of sotagliflozin on epicardial adipose tissue in patients with HFpEF without diabetes.